NUCALA patients had 0.83 asthma attacks/year vs 1.74 in patients taking a placebo fewer asthma attacks in patients with higher eosinophil levels†‡ NUCALA patients with high eosinophil levels in their blood (≥500 cells/mcL) had 0.54 asthma attacks/year vs 2.11 in patients taking a placebo ...
总得来说，Nucala可帮助预防严重的哮喘发作，减少口服类固醇的需求，帮助患者更好的呼吸。而此次获批，使其可在家给药，使用更为方便。参考来源：FDA approves Nucala (mepolizumab) 40 mg prefilled syringe for children with severe eosinophilic asthma 注：本文旨在介绍医药健康研究，不作任何用药依据，具体用药指引...
Let’s get to it withNUCALA. NUCALA is an add-on, prescription maintenance treatment for patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. Learn about taking NUCALA at home Info about NUCALA sent straight to my inbox? Sign me up. B...
EOSINOPHILIC INFLAMMATION IN SEVERE ASTHMA Elevated eosinophils (EOS) are a key driver of asthma pathophysiology.2,3Learn more about eosinophilic inflammation in SEA. LEARN MORE ABOUT EOS IN SEA Eosinophil unit conversion calculator Convert your patient’s lab results to an absolute blood eosinophil co...
1.适用于表现型为嗜伊红性白血球的严重气喘且控制不良(severe refractory eosinophilic asthma)之成人患者之附加维持治疗。 2.使用限制: 美泊利单抗Nucala不可使用于治疗其他嗜伊红性白血病疾病。 美泊利单抗Nucala不可使用于缓解急性支气管痉挛或气喘重积状态(status asthma...
Nucala）是一种调节免疫的药物，主要用于治疗严重的嗜酸性粒细胞增多症（Severe Eosinophilic Asthma）和...
而此次获批,使其可在家给药,使用更为方便。 参考来源:FDA approves Nucala (mepolizumab) 40 mg prefilled syringe for children with severe eosinophilic asthma 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。
美泊利单抗(NUCALA/MEPOLIZUMAB)是一种针对IL-5的人源化单克隆抗体,被批准用于治疗高嗜酸性粒细胞哮喘(eosinophilic asthma)。IL-5是导致嗜酸性粒细胞增多和激活的重要因子,而嗜酸性粒细胞增多被认为是哮喘发作和持续的主要原因之一。因此,通过抑制IL-5,美泊利单抗有可能减少哮喘症状的严重程度和频率。
美泊利单抗(Nucala):国内最新得到批准的生物制剂 作为全球首款针对IL-5(白细胞介素5)的二价人源抗体,美泊利单抗被广泛用于重度嗜酸性粒细胞增多症(Severe Eosinophilic Asthma, SEA)的治疗。近日,美泊利单 美泊利单抗(Nucala):国内最新得到批准的生物制剂
而此次获批,使其可在家给药,使用更为方便。 参考来源:FDA approves Nucala (mepolizumab) 40 mg prefilled syringe for children with severe eosinophilic asthma 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。